1-8 of 8
Andre Robidoux
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P6-01-39: The impact of the 21-gene Recurrence Score® assay upon physician treatment recommendations in the neoadjuvant setting in lymph node-negative breast cancer patients in a multicenter prospective study in Quebec

Mariya Yordanova, Lucas Sideris, Pierre Dubé, Jean-Francois Boileau, Julie Lemieux, Catalin Mihalcioiu, Sylvie Levesque, Marie-Claude Guertin, Erica Patocskai, Rami Younan, André Robidoux, Saima Hassan
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P6-01-39.
https://doi.org/10.1158/1538-7445.SABCS22-P6-01-39
Published: 01 March 2023
View article titled, Abstract P6-01-39: The impact of the 21-gene Recurrence Score® assay upon physician treatment recommendations in the neoadjuvant setting in lymph node-negative breast cancer patients in a multicenter prospective study in Quebec
Journal Articles

Abstract PS4-27: A prospective multicenter study evaluating the impact of the 21-Gene Breast Recurrence Score® upon physician treatment decision and cost in lymph node-positive breast cancer patients in Quebec

Saima Hassan, Rami Younan, Erica Patocskai, Louise Provencher, Brigitte Poirier, Lucas Sideris, Pierre Dubé, Jean-Francois Boileau, Catalin Mihalcioiu, André Robidoux
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS4-27.
https://doi.org/10.1158/1538-7445.SABCS20-PS4-27
Published: 15 February 2021
View article titled, Abstract PS4-27: A prospective multicenter study evaluating the impact of the 21-Gene Breast Recurrence Score<sup>®</sup> upon physician treatment decision and cost in lymph node-positive breast cancer patients in Quebec
Journal Articles

Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC)

Sibylle Loibl, Michael Untch, Marc Buyse, André Robidoux, Luca Gianni, Andreas Schneeweiss, Pierfranco Conte, Martine Piccart, Hervé Bonnefoi, Christian Jackisch, Valentina Nekljudova, Joseph Costantino, Pinuccia Valagussa, Colin Neate, Richard Gelber, Coralie Poncet, Pierre Squifflet, Everardo Saad, Dominik Heinzmann, Carsten Denkert, Charles E Geyer, Jr., Javier Cortes, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael, Gunter von Minckwitz, Norman Wolmark, Patricia Cortazar
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P5-06-02.
https://doi.org/10.1158/1538-7445.SABCS19-P5-06-02
Published: 15 February 2020
View article titled, Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC)
Journal Articles

Abstract 4320: Genomic change in residual triple-negative breast cancers after neoadjuvant chemotherapy

Adriana Aguilar-Mahecha, Ewa Przybytkowski, Josiane Lafleur, Cathy Lan, Stephanie Légaré, Najmeh Alirezaie, Carole Séguin, Federico Discepola, Bojan Kovacina, Catalin Mihalcioiu, André Robidoux, Elizabeth Marcus, Josée Anne Roy, Manuela Pelmus, Olga Aleynikova, Sheida Nabavi, Jacek Majewski, Mark Basik
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4320.
https://doi.org/10.1158/1538-7445.AM2015-4320
Published: 01 August 2015
View article titled, Abstract 4320: Genomic change in residual triple-negative breast cancers after neoadjuvant chemotherapy
Journal Articles

Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40

Harry D Bear, Gong Tang, Priya Rastogi, Charles E Geyer, Qing Liu, André Robidoux, James N Atkins, Luis Baez-Diaz, Adam M Brufsky, Rita S Mehta, Louis Fehrenbacher, James A Young, Francis M Senecal, Rakesh Gaur, Richard G Margolese, Paul T Adams, Howard M Gross, Joseph P Costantino, Soonmyung Paik, Sandra M Swain, Eleftherios P Mamounas, Norman Wolmark
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): PD2-1.
https://doi.org/10.1158/1538-7445.SABCS14-PD2-1
Published: 01 May 2015
View article titled, Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40
Journal Articles

Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer

Jacobs A Samuel, John W Wilson, Hanna Bandos, Richard M Elledge, André Robidoux, Louis Fehrenbacher, Patrick J Ward, Johnathan Polikoff, Adam M Brufsky, Louise Provencher, Alexander HG Paterson, John T Hamm, Robert L Carolla, Luis Baez-Diaz, Priya Rastogi, Thomas B Julian, D Lawrence Wickerham, Sandra M Swain, Charles E Geyer, Jr, Eleftherios P Mamounas, Norman Wolmark
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): S3-02.
https://doi.org/10.1158/1538-7445.SABCS14-S3-02
Published: 01 May 2015
View article titled, Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer
Journal Articles

Abstract P3-12-01: Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide

Patricia A Ganz, John W Wilson, Hanna Bandos, André Robidoux, Alexander HG Paterson, Johnathan Polikoff, Luis Baez-Diaz, Adam M Brufsky, Louis Fehrenbacher, Aroop Mangalik, Patrick J Ward, Louise Provencher, John T Hamm, Philip J Stella, Robert L Carolla, Richard G Margolese, Henry R Shibata, Edith A Perez, Norman Wolmark
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-12-01.
https://doi.org/10.1158/1538-7445.SABCS14-P3-12-01
Published: 01 May 2015
View article titled, Abstract P3-12-01: Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide
Journal Articles

Frequency of the CHEK2 1100delC Mutation among Women with Breast Cancer: An International Study

Shiyu Zhang, Catherine M. Phelan, Phil Zhang, Francois Rousseau, Parviz Ghadirian, Andre Robidoux, William Foulkes, Nancy Hamel, David McCready, Maureen Trudeau, Henry Lynch, Douglas Horsman, Maria Lourdes Leon De Matsuda, Zeba Aziz, Magda Gomes, Mauricio Magalhaes Costa, Alexander Liede, Aletta Poll, Ping Sun, Steven A. Narod
Journal: Cancer Research
Cancer Res (2008) 68 (7): 2154–2157.
https://doi.org/10.1158/0008-5472.CAN-07-5187
Published: 01 April 2008
View article titled, Frequency of the <em>CHEK2</em> 1100delC Mutation among Women with Breast Cancer: An International Study
Open the PDF for Frequency of the <em>CHEK2</em> 1100delC Mutation among Women with Breast Cancer: An International Study in another window